This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Safety and Efficacy of TP10, a Complement Inhibitor, in Adult Women Undergoing Cardiopulmonary Bypass Surgery

This study has been completed.
Information provided by:
Avant Immunotherapeutics Identifier:
First received: April 29, 2004
Last updated: July 19, 2007
Last verified: July 2007
The purpose of this study is to determine if the study drug (TP10), which blocks complement release, can reduce such side effects of complement inflammation as chest pain or heart attacks and be taken safely in women who undergo cardiopulmonary bypass surgery.

Condition Intervention Phase
Myocardial Ischemia Coronary Arteriosclerosis Aortic Valve Insufficiency Mitral Valve Insufficiency Drug: TP10 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double

Further study details as provided by Avant Immunotherapeutics:

Primary Outcome Measures:
  • Reduction in death & myocardial infarction (MI)

Estimated Enrollment: 300
Study Start Date: April 2004
Estimated Study Completion Date: December 2005
Detailed Description:
During cardiac surgery, a substance called “complement” is released by the body. This complement causes inflammation, which can lead to side effects such as chest pain, heart attacks, or heart failure. The purpose of this study is to determine if the study drug (TP10), which blocks complement release, can reduce such side events and be taken safely in women.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Female
  • To undergo high-risk cardiac surgery with cardiopulmonary bypass pump (CPB)
  • CABG alone or with valve surgery

Exclusion Criteria:

  • Acute myocardial infarction (heart attack) within a 3 days of entering the study
  • Conditions that may interfere with interpretation of electrocardiogram data
  • History of immune deficiency syndrome
  • Planned supplemental cardiac surgery or other surgery
  • Pregnancy or lactation
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00082121

United States, California
San Francisco, California, United States, 94115
United States, District of Columbia
Washington, District of Columbia, United States, 20010
United States, Florida
Gainesville, Florida, United States, 32610
Orlando, Florida, United States, 32803
Sarasota, Florida, United States, 34239
United States, Georgia
Atlanta, Georgia, United States, 30342
United States, Illinois
Chicago, Illinois, United States, 60612
United States, Maryland
Towson, Maryland, United States, 21204
United States, Massachusetts
Boston, Massachusetts, United States, 02118
Springfield, Massachusetts, United States, 01199
United States, Michigan
Detroit, Michigan, United States, 48202
Lansing, Michigan, United States, 48910
United States, Ohio
Cincinnati, Ohio, United States, 45219
United States, Tennessee
Memphis, Tennessee, United States, 38120
United States, Texas
Houston, Texas, United States, 77030
United States, Virginia
Danville, Virginia, United States, 24541
United States, Wisconsin
Madison, Wisconsin, United States, 53792
Milwaukee, Wisconsin, United States, 53215
Sponsors and Collaborators
Avant Immunotherapeutics
  More Information Identifier: NCT00082121     History of Changes
Other Study ID Numbers: TP10-ACS-002
Study First Received: April 29, 2004
Last Updated: July 19, 2007

Keywords provided by Avant Immunotherapeutics:
cardiac bypass
complement activation

Additional relevant MeSH terms:
Myocardial Ischemia
Coronary Artery Disease
Mitral Valve Insufficiency
Aortic Valve Insufficiency
Pathologic Processes
Heart Diseases
Cardiovascular Diseases
Vascular Diseases
Coronary Disease
Arterial Occlusive Diseases
Heart Valve Diseases
Complement System Proteins
Immunologic Factors
Physiological Effects of Drugs processed this record on September 21, 2017